London · Delayed Price · Currency is GBP · Price in GBX ValiRx Statistics
Total Valuation
ValiRx has a market cap or net worth of GBP 1.65 million. The enterprise value is 193,936.
| Market Cap | 1.65M |
| Enterprise Value | 193,936 |
Important Dates
The next estimated earnings date is Wednesday, December 16, 2026.
| Earnings Date | Dec 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ValiRx has 1.32 billion shares outstanding. The number of shares has increased by 154.82% in one year.
| Current Share Class | 1.32B |
| Shares Outstanding | 1.32B |
| Shares Change (YoY) | +154.82% |
| Shares Change (QoQ) | +85.23% |
| Owned by Insiders (%) | 5.80% |
| Owned by Institutions (%) | 25.66% |
| Float | 1.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.51 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.98
| Current Ratio | 10.98 |
| Quick Ratio | 10.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -177.90 |
Financial Efficiency
Return on equity (ROE) is -77.28% and return on invested capital (ROIC) is -37.75%.
| Return on Equity (ROE) | -77.28% |
| Return on Assets (ROA) | -36.45% |
| Return on Invested Capital (ROIC) | -37.75% |
| Return on Capital Employed (ROCE) | -64.67% |
| Weighted Average Cost of Capital (WACC) | 0.90% |
| Revenue Per Employee | 2,970 |
| Profits Per Employee | -194,483 |
| Employee Count | 11 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | -125,854 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.37% in the last 52 weeks. The beta is -0.61, so ValiRx's price volatility has been lower than the market average.
| Beta (5Y) | -0.61 |
| 52-Week Price Change | -79.37% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 15.32 |
| Average Volume (20 Days) | 5,551,424 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ValiRx had revenue of GBP 32,672 and -2.14 million in losses. Loss per share was -0.00.
| Revenue | 32,672 |
| Gross Profit | -4,950 |
| Operating Income | -1.71M |
| Pretax Income | -2.31M |
| Net Income | -2.14M |
| EBITDA | -1.49M |
| EBIT | -1.71M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 970,564 in cash and no debt, with a net cash position of 970,564 or 0.00 per share.
| Cash & Cash Equivalents | 970,564 |
| Total Debt | n/a |
| Net Cash | 970,564 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.64M |
| Book Value Per Share | 0.00 |
| Working Capital | 1.21M |
Cash Flow
In the last 12 months, operating cash flow was -1.36 million and capital expenditures -2,587, giving a free cash flow of -1.36 million.
| Operating Cash Flow | -1.36M |
| Capital Expenditures | -2,587 |
| Depreciation & Amortization | 220,912 |
| Net Borrowing | -6,661 |
| Free Cash Flow | -1.36M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -15.15% |
| Operating Margin | -5,233.68% |
| Pretax Margin | -7,073.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ValiRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -154.82% |
| Shareholder Yield | -154.82% |
| Earnings Yield | -129.63% |
| FCF Yield | -82.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 6, 2020. It was a reverse split with a ratio of 0.008.
| Last Split Date | Apr 6, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
ValiRx has an Altman Z-Score of -11.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.31 |
| Piotroski F-Score | 3 |